

2 (12.5%) patients had an isolated nonspecific intraventricular conduction defect. The corrected QT interval was normal in all patients.

The mexiletine dose used was 325 (200–600) mg/d, and the mean treatment duration was 46 [2–181] months. According to subjective evaluation as per normal practice, mexiletine was considered ineffective in controlling myotonia in 31%, partially effective temporarily (reason for stopping) in 50%, and very effective in 19%, who remain on this treatment to date. In none of the patients was it stopped due to cardiac complications; 25% had gastrointestinal upset that did not require medication withdrawal.

During treatment there were no significant cardiovascular events such as syncope, pacemaker requirement, atrioventricular block, bundle-branch re-entry ventricular tachycardia, or sudden cardiac death. On serial ECGs, the onset of left anterior fascicular block was documented in 1 patient, and in another patient, right bundle branch block, which was initially rate-dependent and then later became established during treatment.

After stopping treatment, during follow-up of the cohort, 2 pacemakers were implanted: 1 for symptomatic sinus node dysfunction and another in an asymptomatic patient with onset of first-degree atrioventricular block and complete bundle branch block with pathological prolongation of the HV interval on the electrophysiology study done as standard. There were 4 deaths (25%), 2 due to stroke, 1 due to pneumonia, and 1 due to severe respiratory failure.

In conclusion, the long-term use of mexiletine to improve myotonia in patients with DM1 without severe conduction defects on baseline ECG, even at high doses, does not appear to be associated with an increased cardiac risk and shows evidence of modest effectiveness. The limitations inherent to the retrospective nature of this cohort study must be taken into account when evaluating the results, which should be supported with a prospective study.

FUNDING

None.

AUTHORS' CONTRIBUTIONS

R. Salguero-Bodes: study conception, data collection, analysis, and manuscript writing. A. Ruiz-Curiel: data collection, analysis, manuscript review. Remaining authors: participation in conception and critical review of the manuscript.

CONFLICTS OF INTEREST

There are no potential conflicts of interest.

Rafael Salguero-Bodes,^{a,b,c,*} Aníbal Ruiz-Curiel,^a Julián Palomino-Doza,^{a,b} María Valverde-Gómez,^{a,b,c} Cristina Domínguez-González,^{d,e} and Fernando Arribas-Ynsaurriaga^{a,b,c}

^aServicio de Cardiología, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain

^bCentro de Investigación Biomédica en Red de enfermedades Cardiovasculares (CIBERCV), Spain

^cDepartamento de Medicina, Facultad de Medicina, Universidad Complutense, Madrid, Spain

^dUnidad de Neuromuscular, Servicio de Neurología, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain

^eCentro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Spain

* Corresponding author:

E-mail address: rsbodes@gmail.com (R. Salguero-Bodes).

Available online 11 June 2021

REFERENCES

1. Brook JD, McCurrach ME, Harley HG, et al. Molecular-basis of myotonic-dystrophy expansion of a trinucleotide (CTG) repeat at the 3'-end of a transcript encoding a protein-kinase family member. *Cell*. 1992;68:799–808.
2. Berg J, Jiang H, Thornton CA, et al. Truncated CIC-1 mRNA in myotonic dystrophy exerts a dominant-negative effect on the Cl current. *Neurology*. 2004;63:2371–2375.
3. Logigian EL, Martens WB, Moxley RT, et al. Mexiletine is an effective antimyotonia treatment in myotonic-dystrophy type-1. *Neurology*. 2010;74:1441–1448.
4. Groh WJ. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. *Neurology*. 2011;76:409–409.
5. Heatwole C, Luebbe E, Rosero S, et al. Mexiletine in myotonic dystrophy type 1: a randomized, double-blind, placebo-controlled trial. *Neurology*. 2021;96:e228–e240.
6. Vio R, Zorzi A, Bello L, et al. Evaluation of mexiletine effect on conduction delay and bradyarrhythmic complications in patients with myotonic-dystrophy type-1 over long-term follow-up. *Heart Rhythm*. 2020;17:1944–1950.

<https://doi.org/10.1016/j.rec.2021.04.016>

1885-5857/© 2021 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Dilated cardiomyopathy and mild limb girdle muscular dystrophy caused by the p.Gly424Ser genetic variant in the fukutin gene



Miocardopatía dilatada y distrofia muscular de cinturas leve causada por la variante genética p.Gly424Ser en fukutina

To the Editor,

Dystroglycanopathies are a heterogeneous group of autosomal recessive disorders with a broad clinical spectrum.¹ They include congenital muscular dystrophy, limb girdle muscular dystrophy (LGMD), and dilated cardiomyopathy (DCM). They are characterized by hypoglycosylation of α -dystroglycan, which is essential for muscle integrity. Fukutin is one of the proteins involved in its

glycosylation and in the pathophysiology of the dystroglycanopathies.² We report the first case described in Europe of a patient with DCM and LGMD who is homozygous for the p.Gly424Ser genetic variant in the fukutin gene (*FKTN*) and provide histological confirmation of the resulting abnormality.

A 28-year-old man consulted due to limb weakness and myalgia, with no cardiac symptoms. He showed a 4/5 strength loss in the lower limbs, pseudohypertrophy of the triceps surae and gastrocnemius, atrophy of the quadriceps, positive Gower's sign (use of the upper limbs to get up), and elevated creatine kinase (CK; 6220 U/L). Electromyography showed moderate myopathy in all 4 limbs. Electrocardiography revealed sinus rhythm, a short PR interval, and negative lateral Q and T waves, whereas echocardiography showed DCM with 30% left ventricular ejection fraction.




Figure 1. A: electrocardiogram. B: echocardiogram. C: creatine kinase (CK) trends. D: family tree. *FKTN*: fukutin gene.

After ruling out coronary heart disease, we began treatment with carvedilol and enalapril. The workup was completed with a genetic study of the dystrophin gene, which was normal. Written consent was obtained from the patient for the presentation and publication of this article, including the images. Approval was also received from the institutional ethics committee.

The patient was cardiologically and neurologically stable for 15 years. At 43 years of age, he started showing progressive dyspnea on moderate exertion and was admitted with heart failure and in cardiogenic shock. Electrocardiography (figure 1A) revealed biatrial enlargement, left anterior fascicular block, and lateral Q waves. Echocardiography (figure 1B) showed DCM with severe

dysfunction (20% left ventricular ejection fraction) and akinesia in inferolateral segments. He received optimal neurohormone treatment and underwent automatic defibrillator implantation. Due to unfavorable progression, he required a heart transplant 6 months later. In a histological study, the explanted heart showed extensive biventricular fibrosis.

Five years after the transplant, the patient's myopathy was stable but his CK levels were still elevated (figure 1C). He was referred to the inherited heart disease unit, where a family study was performed. His first-degree relatives were healthy and without myopathy, except his father, who had nonobstructive hypertrophic cardiomyopathy (HCM) (maximum septal thickness,




Figure 2. Histology of the triceps surae muscle. A: (hematoxylin and eosin) muscle fibers with slight variability in the diameter and the occasional internalized nuclei. B: (immunohistochemistry) slight reduction in laminin $\alpha 2$. C: severe reduction in α -dystroglycan vs a healthy control (D).

16 mm). A genetic study performed using next-generation sequencing with a panel of 18 genes (figure 1D) failed to identify any pathogenic variant associated with HCM.

A genetic study performed with next-generation sequencing of the proband (DCM panel, 96 genes) identified the homozygous variant c.1270G>A, p.Gly424Ser in *FKTN*. His parents were heterozygous carriers of this variant. A biopsy of the triceps surae muscle revealed mild muscle involvement, with immunohistochemistry confirming a severe deficit in α -dystroglycan and a slight reduction in laminin α 2; the remainder of the study was normal (figure 2).

Fukutin is a ribitol 5-phosphate (Rbo5P) transferase localized to the Golgi apparatus that functions with fukutin-related protein to add Rbo5P pairs to α -dystroglycan, which is mainly expressed in the skeletal muscle, heart, and brain.² Homozygous and heterozygous carriers of *FKTN* variants show a wide phenotypic spectrum, caused by loss of fukutin function. *FKTN* was initially described in Japan as a cause of Fukuyama-type congenital muscular dystrophy; it was identified as the founder variant of that country and was also linked to Walker-Warburg syndrome: both conditions comprise a severe phenotype with cerebral involvement and short life expectancy. Cases were subsequently described around the world, as well as milder phenotypes with no cerebral involvement, such as LGMC (type R13). Generally, missense variants cause a milder phenotype, whereas nonmissense variants cause a more severe form, although there are exceptions.³ The clinical symptoms of DCM become apparent from the second decade of life and an infrequent form of DCM with limited or absent muscle involvement has been described.^{1,4,5} It seems that there is a dissociation between the muscle and cardiac involvement; fukutin has been reported to have other functions and to be essential in the heart to maintain contractility, calcium homeostasis, Golgi apparatus integrity, and mitochondrial stress resistance.⁶

The p.Gly424Ser variant is localized to a region involved in the phosphorylation of the C-terminal end of *FKTN*. It appears with low frequency (< 0.01%) in the control population in gnomAD, without homozygous carriers; the affected residue is highly conserved and replacement of glycine with serine is classified as pathogenic in bioinformatic predictions. It has recently been reported, also in homozygosis, in 2 Mexican siblings with DCM who died at 20 and 21 years of age, with no apparent neuromuscular involvement⁴; however, no information was provided on CK status or the histological results.

Our case, the first described in Europe, confirms the probable pathogenicity of the p.Gly424Ser variant in *FKTN*. This variant is associated with mild LGMC that is predominated by cardiac involvement in the form of DCM. This case highlights the importance of genetic studies in patients with DCM and muscle involvement and even in isolated cases, given the possibility of autosomal recessive inheritance.

FUNDING

No funding has been received to perform this study.

AUTHORS' CONTRIBUTIONS

J.M. Larrañaga-Moreira and R. Barriales-Villa performed the design, figures, and drafting of the manuscript. P. Blanco-Arias

helped to perform the genetic study and critical analysis. B. San Millán-Tejado assisted with the histological study, figure 2, manuscript revision, and critical analysis. G. Barge-Caballero and M.G. Crespo-Leiro helped in the manuscript drafting and critical analysis.

CONFLICTS OF INTEREST

P. Blanco-Arias is an employee of Health in Code S.L. The other authors do not declare conflicts of interest.

José M. Larrañaga-Moreira,^{a,b,c,d,*} Patricia Blanco-Arias,^e Beatriz San Millán-Tejado,^{d,f} Gonzalo Barge-Caballero,^{b,c,d,g,h} María G. Crespo-Leiro,^{b,c,d,g,h} and Roberto Barriales-Villa^{a,b,c,d,h}

^aUnidad de Cardiopatías Familiares, Complejo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain

^bInstituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain

^cFaculdade de Medicina, Universidade da Coruña (UDC), A Coruña, Spain

^dServizo Galego de Saúde (SERGAS), Spain

^eÁrea de Neurología, Health in Code S.L., A Coruña, Spain

^fServicio de Anatomía Patológica, Neuropatología, Hospital Álvaro Cunqueiro, Vigo, Pontevedra, Spain

^gUnidad de Insuficiencia Cardíaca Avanzada y Trasplante Cardíaco, Complejo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain

^hCentro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain

* Corresponding author:

E-mail address: c.larranaga88@gmail.com

(J.M. Larrañaga-Moreira).

Available online 11 June 2021

REFERENCES

- Murakami T, Hayashi YK, Noguchi S, et al. Fukutin gene mutations cause dilated cardiomyopathy with minimal muscle weakness. *Ann Neurol*. 2006;60:597–602.
- Kanagawa M, Kobayashi K, Tajiri M, et al. Identification of a post-translational modification with ribitol-phosphate and its defect in muscular dystrophy. *Cell Rep*. 2016;14:2209–2223.
- Yis U, Uyanik G, Heck PB, et al. Fukutin mutations in non-Japanese patients with congenital muscular dystrophy: Less severe mutations predominate in patients with a non-Walker-Warburg phenotype. *Neuromuscul Disord*. 2011;21:20–30.
- Villarreal-Molina MT, Rosas-Madrigal S, López-Mora E, et al. Homozygous fukutin missense mutation in two Mexican siblings with dilated cardiomyopathy. *Rev Invest Clin*. 2020. <http://dx.doi.org/10.24875/RIC.20000277>.
- Arimura T, Hayashi YK, Murakami T, et al. Mutational analysis of fukutin gene in dilated cardiomyopathy and hypertrophic cardiomyopathy. *Circ J*. 2009;73:158–161.
- Ujihara Y, Kanagawa M, Mohri S, et al. Elimination of fukutin reveals cellular and molecular pathomechanisms in muscular dystrophy-associated heart failure. *Nat Commun*. 2019;10:5754.

<https://doi.org/10.1016/j.rec.2021.04.015>

1885-5857/ © 2021 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.